Introduction
Chronic lymphocytic leukemia (CLL) has a variable clinical course that is often difficult to predict. 1 Consequently, numerous studies have focused on identifying novel prognostic markers that can prospectively define patient subgroups that have indolent or aggressive disease. [2] [3] [4] [5] In this regard, the discovery that CLL is comprised of two distinct subsets with either mutated or unmutated V H genes, unmutated cases having a significantly inferior prognosis, has redefined both clinical and basic research into this condition. 6, 7 These two seminal papers that elucidated this new classification proposed that CLL might originate from two different stages of B-cell development, that is, pre-and postgerminal center. One of these papers showed a strong correlation between V H gene mutational status and CD38 expression in CLL, 6 where unmutated cases displayed a higher percentage of CD38 þ cells (430%) than mutated cases (o30%). Furthermore, a study by Ghia et al. 8 suggested that the presence of a distinct CD38 þ population within the leukemic population, irrespective of its size, correlated with V H gene mutational status and was predictive of progressive disease. CD38 expression has emerged as an important prognostic marker in CLL but to-date the underlying biological reason why this parameter has prognostic significance remains largely unexplained.
CD38 is a 45 kDa type II transmembrane glycoprotein that possesses both catalytic and signaling properties in a number of different hematological cell types. [9] [10] [11] [12] [13] Among these disparate roles, CD38 has been reported to be involved in lymphocyte activation and ligation of CD38 using a monoclonal antibody agonist has been shown to produce diverse responses including growth, differentiation and apoptosis.
14 Several groups have suggested that CD38 may be involved in signaling through the B-cell receptor (BCR) in CLL, [15] [16] [17] and in this regard we have recently shown an association between CD38 expression and the tyrosine kinase ZAP-70. 18 Furthermore, a recent study has shown an association between CD38 expression, activation marker expression and differential responses to interferon stimulation. 19 In this study, we isolated CD38 þ and CD38 À sub-populations from patients with bimodal expression of the CD38 antigen to elucidate a biological mechanism for the adverse impact of CD38 expression in CLL.
Methods

Patients
Freshly isolated peripheral blood samples from 30 CLL patients with bimodal expression of CD38 (22 male and eight female) were obtained with the patients' informed consent. A total of 42% of the patients had previously received treatment, but all had been treatment-free for at least 3 months before the start of the study. A total of 17 cases had mutated V H genes and 13 had unmutated V H genes. Patient selection was based purely on a definitive diagnosis of CLL the receipt of the patients' consent and bimodal expression of the CD38 antigen. Clinical staging was based on the Binet system.
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V H gene mutation analysis
The V H gene mutational status of the CD38 þ and CD38 À CLL samples was analysed according to the method described previously. 21 The resulting polymerase chain reaction products were sequenced using BIG dye terminator sequencing kit version 3 (Applied Biosystems, Warrington, UK) and the sequences analysed using Ig BLAST (http://www.ncbi.nlm.nih. gov/igblast/) and the IMGT database (http://imgt.cines.fr/vquest/). Both databases gave concordant results in terms of segment usage but often gave slightly different percentage germline sequence homology. However, none of these differences resulted in a change in mutational status of an individual patient. The sequences with a germline homology of 98% or higher were considered unmutated and less than 98% as mutated.
Immunophenotyping for CD38 expression
Freshly isolated CLL lymphocytes from all 30 patients were separated by density centrifugation on Ficoll-Hypaque (Sigma, Poole, UK). Aliquots (1 Â 10 6 cells) were then stained with anti-CD5-FITC or anti-k-FITC or anti-l-FITC (Dako, Ely, UK), anti-CD19-APC (Caltag, Burlingame, CA, USA) and anti-CD38-PE (Caltag). Isotype-matched negative control antibodies (Dako) were employed to set the thresholds for nonspecific binding and the percentage of CD5/CD19 double-positive lymphocytes that expressed CD38 was calculated for each patient sample. All analyses were performed on a FACSCalibur flow cytometer (Becton Dickinson, Oxford, UK) using CellQuest software.
Cell sorting
For all of the micro-array experiments, freshly isolated CLL cells were triple-labelled with CD5-FITC, CD38-PE and CD19-APC. These cells were then physically sorted into CD5
þ subpopulations by highspeed cell sorting (10 000-30 000 cells/s) using a MoFlo High Speed Cell Sorter (Dako). The resultant cell populations were aliquoted and processed for downstream RNA extraction and microarray analysis. The in vitro cell culture and protein analysis experiments were performed on cell-sorted dual-labelled CLL cells (CD38 þ /CD19 þ and CD38 À /CD19 þ ) in order to facilitate the subsequent labelling of these purified sub-populations with various FITC-labelled antibodies. It should be noted that in every case the light chain restricted CD5 þ /CD19 þ lymphocyte population accounted for more than 95% of the total B-cell population indicating that the normal residual B-cell population was unlikely to 'contaminate' significantly any of the CLL samples under investigation.
Microarray procedures
The detailed protocol for sample preparation and microarray processing is available from Affymetrix (http://www.affymetrix. com). Briefly, total RNA was extracted from cell-sorted CD38 þ and CD38
À sub-clones and first strand complementary DNA (cDNA) was synthesized from 5 mg total RNA using a T7-(dT) 24 primer (Genset Corp, San Diego, CA, USA) and reversetranscribed with the Superscript Double-Stranded cDNA Synthesis Kit (Invitrogen Life Technologies, San Diego, CA, USA). After second strand synthesis, the resulting cDNA was subjected to an in vitro transcription reaction using a Bioarray kit (Enzo Diagnostics, New York, NY, USA) to generate biotinylated cRNA. This was subsequently fragmented and hybridized to the Affymetrix U133A GeneChip which contains B23 500 sequences derived from the Genebank database. After hybridization, each microarray was washed, stained and scanned with an argon-ion confocal laser, with excitation at 488 nm and detection at 570 nm.
Flow cytometric analysis of Mcl-1, VEGF, IL-1b and VEGFR-2 protein expression
Freshly isolated CLL lymphocytes derived from patients with bimodal expression of CD38 were analysed by triple-colour immunofluorescent staining using CD38-PE and CD19-APC antibodies in conjunction with anti-Mcl-1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-vascular-endothelial growth factor (VEGF) (R&D Systems, Oxon, UK), anti-interleukin (IL)-1b (Santa Cruz Biotechnology) or anti-VEGFR-2 (R&D Systems, Abingdon, UK). Briefly, 1 Â 10 6 cells were incubated with 20 ml anti-CD38-PE (Caltag) together with 10 ml anti-CD19-APC (Caltag) or isotype-matched negative control antibodies (Dako). The cells were then fixed using a commercially available kit (Dako Cytomation) and resuspended in permeabilization solution together with anti-Mcl-1, anti-VEGF or anti-VEGFR-2. Subsequently, a flourescien isothiocynate (FITC)-conjugated secondary antibody was added (Dako), and the cells were washed and then resuspended in 0.5 ml of 1% paraformaldehyde before flow cytometric analysis on a FACS Calibur flow cytometer (Becton Dickinson). At least 10 000 events were acquired from each sample and non-specific binding was excluded by gating using the isotype-matched negative control antibodies. Gating of the CD38 þ /CD19 þ and CD38 À /CD19 þ leukemic lymphocytes was performed, and the mean fluorescent intensity (MFI) for each protein in these gated subsets was calculated using WinMDI software (J Trotter, Scripps Research Institute, USA).
Cell culture and in vitro apoptosis assay
Freshly isolated CLL cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium (Sigma) supplemented with penicillin, streptomycin and either 10% fetal calf serum (FCS) in the VEGF experiments or 10% autologous serum in the in vitro apoptosis assays. All cultures were incubated at 371C in a humidified 5% carbon dioxide atmosphere. VEGF neutralizing antibody (Sigma) was used at 1 mg/ml and recombinant VEGF was used at 100 ng/ml (Sigma). SU1498, a potent and selective inhibitor of vascular endothelial growth factor receptor 2 kinase activity was used at 10 mM (Calbiochem, Nottingham, UK).
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Apoptosis was quantified using an Annexin V-FITC and propidium iodide labelling assay kit (Bender Medsystems, Vienna, Austria).
VEGF expression measured in cell-sorted subpopulations
In parallel experiments (n ¼ 6 for each cell sorted subpopulation), VEGF expression was monitored in the viable cells, as measured by gating on changes in forward light scatter and side light scatter for the first 5 days of the culture period. This facilitated the analysis of VEGF in the viable cells of sorted cell cultures and the differential viability of CD38 þ /CD19 þ and CD38 À /CD19 þ leukemic lymphocyte sub-populations within the same patient sample. These experiments were performed using FCS rather than autologous serum to remove any interpatient variation in serum VEGF levels. The MFI values recorded were residual values, that is sample -control in all cases.
Western blotting
A total of 1 Â 10 7 freshly isolated CLL cells derived from cell sorted CD38 þ or CD38 À sub-clones were lysed in 1 ml lysis buffer containing 1% Triton X-100. Protein concentration was determined by Bradford assay (Bio-Rad, Hemel Hempstead, UK). Each sample (10 mg protein) was separated on a 4-12% BisTris acrylamide gel and transferred to polyvinylidene fluoride membrane (Bio-Rad). Western blots were incubated with mouse monoclonal antibodies against Mcl-1, interleukin (IL)-1b (Santa 
Statistical analysis
All of the paired protein expression data derived from CD38 þ and CD38
À sub-clones were tested for normality using the Kolmogorov-Smirnov (KS) test. In every case, the data were deemed to be Gaussian or approximately Gaussian so the datasets were compared using the paired Student t-test. All statistical tests were performed using the Graphpad Prism 3.0 software (Graphpad Software, San Diego, CA, USA). Affymetrix gene expression data were processed using Genespring 7.0. Data were normalized to the global median expression value. Genes that showed less than a twofold difference between CD38 þ and CD38 À samples were excluded from further analysis. The remaining genes were considered informative and were subjected to analysis of variance (ANOVA).
Results
CD38
þ and CD38 À sub-populations derived from the same patient are monoclonal Bimodal expression of the CD38 antigen in some CLL patients offers the potential for investigating the biological effect of CD38 expression in CLL cells against a homogeneous genotypic background. We established that CD38 þ and CD38 À subpopulations in bimodal samples had the same light-chain restriction (monotypic) by three-color flow cytometry using a combination of anti-k, anti-l or anti-CD5 in conjunction with anti-CD38 and anti-CD19. All of the samples tested showed a dominant CD5 þ /CD19 þ , light chain restricted, B-cell population accounting for at least 95% of the total B-cell population. Next we physically cell sorted CD38 þ and CD38 À subpopulations and analysed their V H gene mutational status using Biomed-2 primers and subsequent sequence analysis. In the eight cases, we investigated the V H gene usage and base sequences derived from paired CD38 þ and CD38 À samples were identical (Table 1) .
Gene expression profiling of CD38
þ and CD38 À
sub-clonal populations
We performed gene expression profiling experiments on cell sorted CD5
À sub-populations derived from six patients with bimodal expression of the CD38 antigen. The raw experimental data are available via the internet (http://www.ncbi.nlm.nih.gov/geo/). Figure 1a shows bivariate dotplots of CD19 and CD38 expression for all six patient samples. These plots were derived from a serial gating strategy defined by a primary lymphocyte gate and a secondary CD5 þ /CD19 þ gate. Hierarchical clustering successfully discriminated between CD38 þ and CD38 À samples (Figure 1b) . Subsequently, we used a twofold gene expression filter followed by ANOVA statistical analysis to reveal 62 differentially expressed genes between CD38 þ and CD38
À CLL cells (Figure 1c ). Of these, 35 were relatively overexpressed (one of which was CD38) and 27 were relatively under expressed in CD38 þ CLL cells. The gene list, together with Genebank accession numbers and mean fold change between CD38 þ and CD38 À populations are given in Supplementary Table 1 . This gene list was exported to Pathway Assist (Stratagene, La Jolla, CA, USA) and was interrogated for direct associations between genes. Five genes were identified; VEGF, IL-1b, CXCL3 and CCL2 and C/EBPd. A number of recent publications have suggested an important role for VEGF in CLL cell survival signaling [23] [24] [25] and in another study CD38 expression was shown to be strongly correlated with intracellular VEGF expression. 26 Given these associations, we focussed our investigation on VEGF expression and its role in the context of CLL cell survival in purified CD38
þ and CD38 À sub-clones.
VEGF, IL-1b and VEGFR-2 protein expression in CD38 þ and CD38 À sub-populations
We performed flow cytometry and western blotting to determine whether VEGF, IL-1b and VEGF receptor-2 (VEGFR-2) were differentially expressed in CD38 þ and CD38 À sub-clones derived from the same patient. Triple colour flow cytometry facilitated the differential analysis of each protein in CD38 þ / CD19 þ and CD38 À /CD19 þ CLL cells without the necessity to physically sort the cells (n ¼ 16 paired samples for each protein analysed). The western blotting assays were performed using
þ sub-populations derived from five individual patients. Both methods revealed a marked increase in VEGF and IL-1b expression in CD38 þ CLL cells when compared with their CD38 À counterparts (Figure 2a and b, respectively), and these differences were statistically significant (Figure 2c) . These experiments validated the gene expression profiling results described previously. In addition, samples derived from the same patient cohort showed elevated expression of VEGFR-2 in CD38 þ CLL cells when compared with their CD38 À counterparts (Figure 2d ) as measured by flow cytometry. Interestingly, Table 1 Light chain restriction as measured by flow cytometry and percentage sequence homology to the closest germline sequence and V H gene usage analysed using Ig BLAST (NCBI) in sorted CD38 + and CD38 À sub-populations derived from the same patient Patient no. Light chain restriction % sequence homology and V H gene usage þ and CD38 À sub-clones after filtering the data using a twofold expression threshold and analysis for statistical significance using both Student's t-test and ANOVA. 35 genes were found to be relatively overexpressed and 27 genes relatively underexpressed in CD38 þ sub-clones.
CD38 expression in CLL C Pepper et al transcription of VEGFR-2 was elevated in CD38 þ CLL cells when compared with their CD38 À counterparts but was not above our twofold filter and hence did not appear in the final gene list.
Cell survival in cell-sorted sub-populations
To establish whether the relative overexpression of VEGF was biologically important to CD38 þ CLL cells, we analysed in vitro survival in cell-sorted CD38 þ and CD38 À sub-clones. Control cultures were also analysed in which the CD38 þ and CD38
À cell sorting gates were merged to yield a mixed 'unsorted' population that had been subjected to the same cell sorting stresses (n ¼ 6 for each purified sub-population). In these experiments, we used autologous serum because it has been shown to minimize spontaneous apoptosis. 27 The CD38 þ subclones showed a consistently lower level of spontaneous apoptosis when compared with the CD38 À sub-clones and the mixed cultures at all the time points tested (Figure 3a) . The purified CD38
À CLL cells showed the highest percentage apoptosis and the mixed cultures were less viable than the CD38 þ sub-clones, but more viable than the CD38 þ and CD38 À sub-clones were separated by high-speed cell sorting and were subsequently Western blotted using the same anti-VEGF and anti-IL-1b antibodies employed in the flow cytometry assays. CD38 þ sub-clones showed higher expression of VEGF and IL-1b as evidenced by higher VEGF/b-actin and IL-1b/b-actin ratios than their paired CD38 À counterparts as measured by densitometric analysis. (c) Flow cytometric analysis of samples derived from 16 CLL patients revealed that the mean expression values for VEGF and IL-1b were significantly higher in CD38 þ sub-clones when compared to their CD38 À sub-clones in (P ¼ 0.0002 and 0.0008, respectively). (d) Flow cytometric analysis of samples derived from 16 CLL patients revealed that VEGFR-2 expression was significantly higher in CD38 þ sub-clones when compared to their CD38 À sub-clones in (P ¼ 0.001).
CD38 expression in CLL
þ sub-clones can confer an in vitro cytoprotective effect on CD38 À sub-clones through direct cell-cell contact or secretion of survival factors.
VEGF expression measured in cell-sorted sub-populations
In parallel experiments (n ¼ 6 for each purified sub-population), we cultured sorted CLL cells with FCS rather than autologous serum. In these cultures we measured VEGF expression by flow cytometry in the viable cells, gated using changes in forward light scatter and side light scatter, up to day 5 of the culture period. FCS was used in these experiments to minimize the influence of differential amounts of serum VEGF derived from individual patients. Figure 3b shows overlaid histogram plots of VEGF expression (solid histograms) and isotype-matched controls (open histograms) in viable CLL cells following 72 h culture. The CD38 þ sub-clones consistently showed higher levels of VEGF than either their CD38
À counterparts or the 'unsorted' CLL controls (Figure 3c ).
Mcl-1 expression in CD38
þ and CD38 À sub-clones VEGF has been shown previously to modulate the expression of the anti-apoptotic protein Mcl-1 in both multiple myeloma and CLL. 25, 28 We therefore investigated the expression of Mcl-1 in viable CD38
þ and CD38 À sub-clones derived from the same patient to determine whether differential expression of this protein may contribute to the enhanced cytoprotective phenotype exhibited by CD38 þ CLL cells. Viable CLL cells were gated using forward light scatter and side light scatter to exclude the detection of the Mcl-1 cleavage product resulting from apoptosis induction. 29 In all the samples tested, (n ¼ 25) we found that CD38 þ sub-clones showed a consistent over expression of Mcl-1 when compared to their CD38 À counterparts (Figure 4a ). This was confirmed by western blotting of cell-sorted CD38 þ and CD38
À sub-clones derived from five patients. Figure 4b shows paired samples derived from two individual patients. Mcl-1 and b-actin were quantified using scanning densitometry and the ratio of Mcl-1/b-actin is shown for each sample.
VEGF inhibition in cell-sorted CD38
sub-clones
It has previously been shown that CLL cells constitutively produce VEGF in culture 30 and that CD38 expression correlates with VEGF expression. 31 Further, it has recently been shown that autocrine VEGF signalling provides a degree of cytoprotection to CLL cells in vitro. 23 In this study, we investigated whether inhibition of VEGF differentially altered the in vitro survival of CD38 þ and CD38 À sub-clones derived from the same patient. VEGF was blocked in two ways: by neutralizing monoclonal antibody and by inhibiting VEGF receptor signaling using SU1498 a potent and selective inhibitor of vascular endothelial growth factor receptor 2 kinase activity. 22 Treatment with the antibody had little effect on the viability of cell-sorted CD38 þ or CD38
À CLL cells. In contrast, SU1498 caused a significant increase in apoptosis in both CD38 þ and CD38 À CLL cells (Figure 5a ).
Cytoprotective effect of recombinant VEGF in CD38
þ or CD38
À CLL cells
When recombinant VEGF was added to cultures containing purified CD38 þ or CD38 À CLL cells both sub-clonal populations demonstrated a decrease in spontaneous apoptosis (Figure 5b) . Interestingly, the CD38 À CLL cells were more sensitive to the cytoprotective effects of recombinant VEGF, despite showing lower levels of VEGFR-2 than their CD38 þ counterparts (Figure 2d ). This VEGF-induced cytoprotection was associated with a marked increase in Mcl-1 expression in CD38 À sub-clones and a smaller increase in CD38 þ sub-clones (Figure 5c ). Despite the upregulation of Mcl-1 expression in CD38 À CLL cells in the presence of recombinant VEGF, these sub-clones failed to achieve Mcl-1 expression levels equivalent to the basal Mcl-1 expression levels of their CD38 þ counterparts.
Discussion
CD38 expression is an important prognostic tool in CLL with high levels being associated with shorter time to first treatment and overall survival. [32] [33] [34] Here, we show for the first time that CD38
þ CLL cells possess a distinct gene expression profile when compared with CD38
À sub-clones derived from the same patient. Importantly, we found that sub-clonal populations derived from our bimodal patients not only showed the same light chain restriction (monotypic) but also possessed identical V H gene sequences (monoclonal). Hence the paired CD38 þ and CD38
À sub-populations from the individual patients investigated in this study were derived from a single malignant transforming event and differences in gene expression between them cannot be explained by a heterogenous genetic background. Neither can they be explained by preferential antigendriven somatic hypermutation in one sub-clone. Moreover, the expression of the CD38 antigen defines a sub-population of CLL cells with a distinct transcriptional profile that may be the cause or effect of an increase in cellular activation. 35, 36 A number of recent studies have demonstrated an important role for VEGF in CLL 23-25,37-39 and one described an association between VEGF and CD38. 26 Directed by the differential transcription of VEGF revealed in our gene expression profiling data, we confirmed that CD38 þ CLL cells contained more VEGF protein than their CD38 À counterparts derived from the same patient. The elevated VEGF expression in CD38 þ CLL cells was associated with increased in vitro cytoprotection and this could be abrogated, at least in part, by the use of an inhibitor of VEGFR-2 signaling, SU1498. In contrast, the use of an anti-VEGF blocking antibody had no significant effect on CLL cell survival in our purified cell-sorted cultures indicating that exogenous VEGF is not required to promote CLL cell survival in this setting. However, the addition of recombinant VEGF caused a significant reduction in spontaneous apoptosis in CD38 À CLL cells despite the fact that these cells expressed less VEGFR-2 than their CD38 þ counterparts. Therefore, we conclude that CD38 þ CLL preferentially cells utilize an internal autocrine VEGF survival loop that cannot be readily inhibited by anti-VEGF blocking antibodies. In contrast, CD38
À CLL cells produce less of their own VEGF and seem to benefit from additional exogenous VEGF to maintain cell viability. In the context of bimodal patients, exogenous VEGF might be provided by CD38
þ sub-clones and this could explain, at least in part, the persistence of bimodal patterns of expression in these patients. This notion is supported by our in vitro survival assays in which the CD38 þ CLL cells were able to maintain their VEGF expression and the unsorted cultures showed less spontaneous apoptosis than the purified CD38 À CLL cells. One of the candidate effector molecules regulated by VEGF is the anti-apoptotic protein Mcl-1; previously associated with cellular differentiation, proliferation and resistance to þ and CD38 À sub-clones. (a) CD38 þ and CD38 À sub-clones were cell-sorted from freshly isolated CLL cells from six individual patients and placed in culture for up to 7 days. Apoptosis was measured in the cultures after each 24 h period, and viability was compared with cultures in which the CD38 þ and CD38 À flow sorting gates had been merged to yield an 'unsorted' heterogenous population of CD38 þ and CD38 À sub-clones. The CD38 þ sub-clones showed significantly more resistance to spontaneous apoptosis than their CD38
À counterparts (P ¼ 0.0001). The composite, 'unsorted', population showed less spontaneous apoptosis than purified CD38 À sub-clones, suggesting that the CD38 þ sub-clones can confer a degree of cytoprotection to the CD38 À sub-clones, at least in vitro. CD38 expression in CLL C Pepper et al apoptosis. [40] [41] [42] [43] 
-test). (b) CD38
þ and CD38 À subclones were separated by high-speed cell sorting and were subsequently western blotted using the same anti-Mcl-1 antibody employed in the flow cytometry assays. CD38 þ sub-clones showed higher expression of Mcl-1 than their paired CD38 À counterparts as evidenced by higher Mcl-1/b-actin ratios quantified using densitometric analysis. À sub-clones derived from three different patients with bimodal expression of the CD38 antigen were cultured for 24 h with or without 1 mg/ml of an anti-VEGF neutralizing antibody and/or 10 mM of the VEGF receptor signaling inhibitor SU1498. Treatment with the neutralizing antibody had no significant effect on survival in either the CD38 þ or CD38 À sub-clones. In contrast, the VEGF receptor signaling inhibitor SU1498 caused a significant decrease in cell viability in both sub-clonal populations. (b) CD38 þ and CD38 À subclones derived from eight different patients were cultured for 24 h with or without 100 ng/ml recombinant VEGF. Both the CD38 þ and CD38 À sub-clones showed a decrease in apoptosis in the VEGFtreated cultures but this only reached significance in the CD38 À subclones (P ¼ 0.002). (c) Mcl-1 expression was measured by flow cytometry in the sub-clonal populations cultured with and without the addition of recombinant VEGF for 24 h. Mcl-1 expression was consistently higher in the CD38 þ sub-clones. Both the CD38 þ and CD38 À sub-clones showed an increase in Mcl-1 expression following exposure to VEGF and this was most marked in the CD38 À sub-clones (P ¼ 0.0001).
BCR-mediated signals. 18 It is therefore likely that multiple, dynamic, mechanisms exist for the control of Mcl-1 expression in CLL cells but autocrine VEGF is a critical determinant of basal expression.
Several recent studies have shown that CD38 expression is higher in CLL cells in the bone marrow and lymphoid tissues when compared to peripheral blood. 8, 45 This implies that once CLL cells leave these compartments they begin to lose CD38 expression and by inference, the higher the level of CD38 in the peripheral blood, the higher the degree of renewal/turnover from bone marrow and lymph nodes. Although this is a possibility, it cannot fully explain the consistently high Mcl-1 expression found in CD38
þ CLL cells as Mcl-1 is a labile protein with a half-life of only 1-3 h. 46 Moreover, our data suggest that Mcl-1 expression is actively maintained in peripheral blood CD38
þ CLL cells and that these peripheral blood CLL cells are not merely shadows of a more vibrant counterpart in the bone marrow or lymph nodes. In support of this concept, our microarray data show that CD38
þ CLL cells manifest a unique gene signature that is consistent with a heightened capacity to produce autocrine survival signals. Our findings are similar to those recently reported by Hü ttmann et al., 47 in which distinct gene expression signatures were described in CLL prognostic subgroups defined by ZAP-70 and CD38 expression.
Taken together, our data present direct evidence that differential gene expression may contribute to the poor prognosis associated with CD38 expression in CLL. Furthermore, the finding that both VEGF and Mcl-1 are differentially expressed in CD38
þ CLL cells suggests that they may prove to be useful therapeutic targets for the treatment of poor prognosis CLL.
